Eli Lilly Market Value Tops $1.2 Trillion for First Time; Tirzepatide Leads Global Drug Sales in H1 2026
Eli Lilly's market capitalization surpassed $1.2 trillion for the first time on August 19, making it the world's first pharmaceutical company to reach that milestone. Shares closed up 4.46% at $1,280.34, valuing the company at approximately $1.21 trillion. The stock had previously crossed the $1 trillion threshold in November 2025 after rallying from a low of about $620. In 2026, Eli Lilly's dual-target diabetes and weight-loss drug tirzepatide became the world's best-selling medicine in the first half of the year, supporting the shares' continued climb to record highs.
On August 19, Eli Lilly's shares touched an intraday high of $1,292.65 before closing up 4.46% at $1,280.34, giving the company a total market value of approximately $1.21 trillion. This marks the first time any pharmaceutical company has reached such a valuation, making Eli Lilly the world's first drugmaker to break the $1.2 trillion market-capitalization threshold.
Eli Lilly had previously become the first pharmaceutical company to surpass the $1 trillion mark and remains the only drugmaker in the US stock market's "trillion-dollar club." In August 2025, its shares began a sustained rally from a low of about $620, crossing the $1 trillion market-cap threshold in November of that year at a share price of approximately $1,055. Entering 2026, the stock underwent a correction, falling below $850 at the end of April before regaining momentum in May, with market value returning above the trillion-dollar level in late May.
In recent sessions, Eli Lilly's shares have repeatedly challenged record highs as market value continues to climb. Its dual-target diabetes and weight-loss drug tirzepatide became the world's highest-selling medicine in the first half of 2026, with related sales data publicly disclosed.